SRPT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) - Contact Kessler Topaz Meltzer & Check, LLP

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified class period [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the defendants [2]. Group 2: Legal Process and Participation - Investors in Sarepta have until August 25, 2025, to seek appointment as lead plaintiffs in the class action, representing the interests of all class members [3]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case, who will select counsel to represent the class [3]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4]. - The firm emphasizes its commitment to protecting investors and consumers from fraud and negligence [4].